[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Mithraprabhu S, Grigoriadis G, Khong T, Spencer A: Deactylase inhibition in myeloproliferative neoplasms. Invest New Drugs; 2010 Dec;28 Suppl 1:S50-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myeloproliferative neoplasms (MPN) are clonal haemopoietic progenitor cell disorders characterized by the proliferation of one or more of the haemopoietic lineages (myeloid, erythroid and/or megakaryocytic).
  • The MPNs include eight haematological disorders: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), systemic mastocytosis (SM), chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), chronic neutrophilic leukemia (CNL), and unclassifiable MPN (MPN, U).
  • Therapeutic interventions for MPNs include the use of tyrosine kinase inhibitors (TKIs) for BCR-ABL1(+) CML and JAK2 inhibitors for PV, ET and PMF.
  • Histone deacetylase inhibitors (HDACi) are a novel class of drugs capable of altering the acetylation status of both histone and non-histone proteins, thereby affecting a repertoire of cellular functions in neoplastic cells including proliferation, differentiation, immune responses, angiogenesis and survival.
  • This review provides a review of pre-clinical and clinical studies that have explored the use of HDACi as potential therapeutics for MPNs.
  • [MeSH-major] Histone Deacetylase Inhibitors / therapeutic use. Histone Deacetylases / metabolism. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / enzymology
  • [MeSH-minor] Animals. Epigenesis, Genetic / drug effects. Humans. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 2003 Nov 20;46(24):5097-116 [14613312.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):672-7 [14744784.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):627-38 [15023334.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34227-39 [15175350.001]
  • [Cites] Expert Opin Investig Drugs. 2007 May;16(5):659-78 [17461739.001]
  • [Cites] Leuk Res. 2007 Aug;31(8):1115-23 [17267032.001]
  • [Cites] Blood. 2007 Jul 1;110(1):313-22 [17363733.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):503-14 [17610380.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9 [17613547.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6417-24 [17616702.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4280-90 [17634558.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1827-8 [17460705.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5420-32 [17694083.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Sep;322(3):1084-92 [17569822.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]
  • [Cites] Cancer J. 2007 Nov-Dec;13(6):377-83 [18032975.001]
  • [Cites] Leukemia. 2008 Apr;22(4):740-7 [18079739.001]
  • [Cites] Br J Haematol. 2008 May;141(4):504-11 [18318760.001]
  • [Cites] Leukemia. 2008 May;22(5):965-70 [18385750.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1638-40 [18440067.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):375-80 [18636159.001]
  • [Cites] Blood. 2008 Aug 1;112(3):793-804 [18505786.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1636-8 [18305559.001]
  • [Cites] Stem Cells. 2008 Aug;26(8):1920-30 [18511598.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1886-93 [18591380.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6106-15 [18829489.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3065-72 [18650451.001]
  • [Cites] Haematologica. 2008 Nov;93(11):1635-44 [18815196.001]
  • [Cites] Leukemia. 2008 Nov;22(11):1990-8 [18843285.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):185-98 [18804549.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2231-2 [19052966.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2321-7 [19052980.001]
  • [Cites] Nat Rev Genet. 2009 Jan;10(1):32-42 [19065135.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6693-701 [15235588.001]
  • [Cites] Oncogene. 1998 Jul 2;16(26):3461-9 [9692554.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1239-44 [10022130.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2705-12 [15517875.001]
  • [Cites] Int J Mol Med. 2005 Jan;15(1):169-72 [15583844.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1768-76 [15514006.001]
  • [Cites] Med Res Rev. 2005 May;25(3):261-309 [15717297.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):741-3 [15908787.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1579-89 [16015388.001]
  • [Cites] Gene. 2005 Dec 19;363:15-23 [16289629.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):38-51 [16397526.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1188-96 [16444746.001]
  • [Cites] Haematologica. 2006 Apr;91(4):513-21 [16533723.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3339-41 [16352805.001]
  • [Cites] Free Radic Biol Med. 2006 Jun 15;40(12):2175-82 [16785031.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):345-56 [17457302.001]
  • [Cites] Leukemia. 2009 Jan;23(1):180-2 [18509350.001]
  • [Cites] Cancer Lett. 2009 May 8;277(1):8-21 [18824292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 12;106(19):7751-5 [19416910.001]
  • [Cites] Ann Hematol. 2009 Jul;88(7):699-700 [19030859.001]
  • [Cites] Exp Cell Res. 2009 Jul 1;315(11):1809-18 [19268463.001]
  • [Cites] Eur J Haematol. 2009 Jul;83(1):48-56 [19226363.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8A):1437-50 [19522842.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7612-8 [19752087.001]
  • [Cites] Blood. 2009 Dec 3;114(24):5024-33 [19828702.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3109-17 [20130243.001]
  • [Cites] Leuk Res. 2010 Sep;34(9):1132-8 [20206383.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):427-42 [20478526.001]
  • [Cites] Blood. 2006 Jul 15;108(2):645-52 [16537804.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1058-64 [16861352.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1071-6 [16892059.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5869-78 [17020995.001]
  • [Cites] Blood Cells Mol Dis. 2006 Nov-Dec;37(3):210-7 [16978890.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Ann Intern Med. 2006 Dec 19;145(12):913-23 [17179059.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):165-73 [16990584.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Leukemia. 2007 Mar;21(3):505-10 [17230231.001]
  • [Cites] Blood Cells Mol Dis. 2007 May-Jun;38(3):280-6 [17350297.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2049-55 [10766197.001]
  • [Cites] Mol Biol Cell. 2000 Jun;11(6):2069-83 [10848630.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20436-43 [10777477.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):2-11 [10930974.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39223-30 [11010972.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22491-9 [11304533.001]
  • [Cites] Cell Mol Life Sci. 2001 May;58(5-6):728-36 [11437234.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Mol Pharmacol. 2001 Oct;60(4):828-37 [11562446.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Adv Cancer Res. 2002;86:41-65 [12374280.001]
  • [Cites] Semin Hematol. 2003 Jan;40(1):22-33 [12563609.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3236-9 [12446442.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5126-35 [12941844.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3765-74 [12893773.001]
  • (PMID = 21127942.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC3003795
  •  go-up   go-down


2. Jardin F, Vasse M, Debled M, Dominique S, Courville P, Callonnec F, Buchonnet G, Thiberville L, Tilly H: Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma. Am J Hematol; 2005 Nov;80(3):243-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma.
  • A white blood cell count more than 50 x 10(9)/l, not related to bone marrow involvement, is termed leukemoid reaction.
  • We report on the first case of an undifferentiated sarcoma of the lung associated with an intense paraneoplastic neutrophilic leukemoid reaction related to the production of granulocyte colony-stimulating factor (G-CSF).
  • A radiography and a computed tomography scan of the chest revealed a well-limited voluminous and heterogeneous low-density mass of the left lung.
  • The patient died of multiorgan failure related to uncontrolled progressive tumor growth after admission and two cycles of chemotherapy.
  • The G-CSF concentration dramatically increased after the first cycle of chemotherapy and during the subsequent neutropenia, as a result of the tumor lyses as well as of disruption of the physiological negative feedback mechanism.
  • [MeSH-minor] Cell Proliferation. Fatal Outcome. Humans. Leukemia, Neutrophilic, Chronic / etiology. Male. Middle Aged. Multiple Organ Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247754.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


3. Liu KH, Wu CJ, Chou CH, Lee HC, Lee NY, Hung ST, Ko WC: Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol; 2004 Dec;42(12):5950-3
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Candidal meningitis is a rare infectious disease that usually leads to substantial morbidity and mortality.
  • We present a case of candidal meningitis refractory to systemic antifungal therapy (amphotericin B and fluconazole).
  • A 63-year-old female with lymphoblastic lymphoma and myelodysplasia with leukemia transformation developed prolonged fever and headache on the seventh day following intrathecal prophylactic chemotherapy.
  • A lumbar puncture showed neutrophilic pleocytosis, and a cerebrospinal fluid culture yielded Candida albicans.
  • Parenteral therapy with amphotericin B alone or amphotericin B in combination with fluconazole or intrathecal administration of amphotericin B failed to eradicate C. albicans in the cerebrospinal fluid.
  • After 7 days of caspofungin therapy, however, the cerebrospinal fluid became sterile and the patient gradually regained consciousness.
  • She was discharged 1 month after completing 4 weeks of caspofungin therapy.
  • There were two critical issues we thought to be relevant to the favorable outcome of this case.
  • First, isolation of C. albicans was achieved by inoculating enriched liquid medium with cerebrospinal fluid.
  • Second, there is a potential therapeutic benefit of caspofungin in treating a fungal infection of the central nervous system.
  • [MeSH-major] Antifungal Agents / therapeutic use. Candida albicans / isolation & purification. Candidiasis / drug therapy. Immunocompromised Host. Meningitis, Fungal / drug therapy. Peptides, Cyclic / therapeutic use
  • [MeSH-minor] Echinocandins. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Microbiol Infect Dis. 2000 Jul;37(3):169-79 [10904190.001]
  • [Cites] Semin Neurol. 2000;20(3):307-22 [11051295.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Nov;46(11):3634-6 [12384379.001]
  • [Cites] J Microbiol Immunol Infect. 2002 Dec;35(4):249-54 [12542251.001]
  • [Cites] J Antimicrob Chemother. 2003 Jun;51(6):1427-9 [12716772.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1445-57 [12766841.001]
  • [Cites] Clin Infect Dis. 1999 May;28(5):1139-47 [10452649.001]
  • [Cites] Clin Infect Dis. 2004 Jan 15;38(2):161-89 [14699449.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Jan;38(1):83-9 [7511361.001]
  • [Cites] Clin Infect Dis. 1994 Jul;19(1):60-6 [7948559.001]
  • [Cites] Clin Infect Dis. 1995 Aug;21(2):323-7 [8562739.001]
  • [Cites] Clin Infect Dis. 1997 Sep;25(3):673-6 [9314460.001]
  • [Cites] Arch Pathol Lab Med. 1998 Nov;122(11):1030-3 [9822135.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Sep;22(9):575-6 [12938012.001]
  • (PMID = 15583351.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; F0XDI6ZL63 / caspofungin
  • [Other-IDs] NLM/ PMC535248
  •  go-up   go-down


Advertisement
4. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR: Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood; 2005 Oct 15;106(8):2841-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib induces myeloid differentiation of acute myeloid leukemia.
  • Cure rates for patients with acute myeloid leukemia (AML) remain low despite ever-increasing dose intensity of cytotoxic therapy.
  • In an effort to identify novel approaches to AML therapy, we recently reported a new method of chemical screening based on the modulation of a gene expression signature of interest.
  • Among the compounds inducing neutrophilic differentiation was DAPH1 (4,5-dianilinophthalimide), previously reported to inhibit epidermal growth factor receptor (EGFR) kinase activity.
  • Here we report that the Food and Drug Administration (FDA)-approved EGFR inhibitor gefitinib similarly promotes the differentiation of AML cell lines and primary patient-derived AML blasts in vitro.
  • Gefitinib induced differentiation based on morphologic assessment, nitro-blue tetrazolium reduction, cell-surface markers, genome-wide patterns of gene expression, and inhibition of proliferation at clinically achievable doses.
  • Importantly, EGFR expression was not detected in AML cells, indicating that gefitinib functions through a previously unrecognized EGFR-independent mechanism.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1967 Feb;27(2):209-20 [6018555.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):257-63 [14770183.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1413-9 [1884013.001]
  • [Cites] Cancer Res. 1993 Jan 1;53(1):191-6 [7677980.001]
  • [Cites] Cell Growth Differ. 1993 Sep;4(9):769-76 [8241025.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2334-8 [8134396.001]
  • [Cites] J Med Chem. 1994 Apr 1;37(7):1015-27 [8151612.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1916-23 [7544646.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] N Engl J Med. 2004 Dec 2;351(23):2403-7 [15575056.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1785-96 [15514007.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):329-36 [15711537.001]
  • [Cites] Leukemia. 2000 Mar;14(3):491-6 [10720148.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1371-7 [10942231.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4 [11459659.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3496-506 [12032784.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3815-25 [12228201.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4292-302 [12409327.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2074 [12584148.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):922-30 [12796031.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2960-8 [12816863.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1212-8 [14977817.001]
  • [Cites] Cancer Res. 1986 May;46(5):2314-9 [2870796.001]
  • (PMID = 15998836.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5K08 CA098444-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC1895296
  •  go-up   go-down


5. Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D: High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood; 2007 Aug 1;110(3):994-1003
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
  • The inability of myeloid chronic myelogenous leukemia blast crisis (CML-BC) progenitors to undergo neutrophil differentiation depends on suppression of C/EBPalpha expression through the translation inhibitory activity of the RNA-binding protein hnRNP-E2.
  • In fact, high levels of p210-BCR/ABL are required for enhanced hnRNP-E2 expression, which depends on phosphorylation of hnRNP-E2 serines 173, 189, and 272 and threonine 213 by the BCR/ABL-activated MAPK(ERK1/2).
  • Similarly, pharmacologic inhibition of MAPK(ERK1/2) activity decreases hnRNP-E2 binding to the 5'UTR of C/EBPalpha mRNA by impairing hnRNP-E2 phosphorylation and stability.
  • This, in turn, restores in vitro and/or in vivo C/EBPalpha expression and G-CSF-driven neutrophilic maturation of differentiation-arrested BCR/ABL(+) cell lines, primary CML-BC(CD34+) patient cells and lineage-negative mouse bone marrow cells expressing high levels of p210-BCR/ABL.
  • Thus, increased BCR/ABL oncogenic tyrosine kinase activity is essential for suppression of myeloid differentiation of CML-BC progenitors as it is required for sustained activation of the MAPK(ERK1/2)-hnRNP-E2-C/EBPalpha differentiation-inhibitory pathway.
  • Furthermore, these findings suggest the inclusion of clinically relevant MAPK inhibitors in the therapy of CML-BC.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2006 Feb 20;203(2):371-81 [16446383.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2507-16 [16293596.001]
  • [Cites] Neoplasia. 2006 Jan;8(1):1-8 [16533420.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6338-43 [16606850.001]
  • [Cites] Br J Haematol. 2006 May;133(4):400-2 [16643447.001]
  • [Cites] Leuk Res. 1993 Jul;17(7):593-600 [7686992.001]
  • [Cites] Blood. 2006 May 15;107(10):4080-9 [16418324.001]
  • [Cites] Nature. 2006 May 25;441(7092):457-62 [16724058.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6468-72 [16818614.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1353-62 [16670262.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):775-81 [16953242.001]
  • [Cites] Ann Hematol. 2000 Aug;79(8):424-31 [10985361.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):582-4 [14726508.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3167-74 [15070699.001]
  • [Cites] Leuk Res. 2004 Apr;28(4):415-9 [15109543.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4010-22 [14982876.001]
  • [Cites] Curr Pharm Des. 2004;10(16):1907-14 [15180527.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Biotechniques. 1999 Nov;27(5):1032-9, 1042 [10572651.001]
  • [Cites] Leukemia. 2000 Jun;14(6):973-90 [10865962.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6159-69 [10913197.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5487-97 [11114726.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(11):3789-806 [11340171.001]
  • [Cites] Cell. 2001 Oct 19;107(2):247-58 [11672531.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):48-58 [11753385.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):188-99 [11782377.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1332-40 [11830484.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2255-66 [11884611.001]
  • [Cites] RNA. 2002 Mar;8(3):265-78 [12003487.001]
  • [Cites] Blood. 2003 Jan 15;101(2):655-63 [12393654.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):145-60 [12620409.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1267-75 [12702500.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):8012-20 [12970749.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16 [14613031.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52651-9 [14517214.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):675-86 [14701740.001]
  • [Cites] Mol Cell Biol. 1988 Feb;8(2):963-73 [3280975.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3048-51 [2032243.001]
  • [Cites] Oncogene. 1991 Jun;6(6):903-9 [1906157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6293-7 [2068108.001]
  • [Cites] J Biol Chem. 1991 Nov 25;266(33):22159-63 [1939237.001]
  • [Cites] J Biol Chem. 1993 Jul 15;268(20):14553-6 [8325833.001]
  • [Cites] Exp Hematol. 1993 Oct;21(11):1460-6 [8405226.001]
  • [Cites] Leukemia. 1994 Jan;8(1):115-20 [8289476.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2371-8 [7662984.001]
  • [Cites] Cell. 1995 Sep 22;82(6):981-8 [7553858.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3692-7 [7579335.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):811-20 [8642285.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1234-47 [8695841.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4717-25 [8756629.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10838-43 [8855267.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13137-42 [8917557.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13158-63 [8917561.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74 [9012825.001]
  • [Cites] Blood. 1997 Jul 15;90(2):489-519 [9226149.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6151-61 [9321394.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4442-55 [9687511.001]
  • [Cites] J Biol Chem. 1999 Mar 5;274(10):6553-8 [10037749.001]
  • [Cites] Nat Med. 1999 Jul;5(7):810-6 [10395327.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24849-57 [10455157.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10650-60 [15572670.001]
  • [Cites] Immunity. 2004 Dec;21(6):853-63 [15589173.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):534-40 [15846378.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4893-4 [15933063.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1579-89 [16015388.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6432-40 [16007188.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9962-70 [16267021.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):355-68 [16286244.001]
  • (PMID = 17475908.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 078890; United States / NCI NIH HHS / CA / P01 CA078890; United States / NCI NIH HHS / CA / CA 16058; United States / NCI NIH HHS / CA / R01 CA095512; United States / NCI NIH HHS / CA / CA 095512; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / CA 9555111
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / Enzyme Inhibitors; 0 / Heterogeneous-Nuclear Ribonucleoproteins; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ PMC1924762
  •  go-up   go-down


6. Cohen PR: Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis; 2007;2:34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
  • Sweet's syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis.
  • Sweet's syndrome presents in three clinical settings: classical (or idiopathic), malignancy-associated, and drug-induced.
  • Classical Sweet's syndrome (CSS) usually presents in women between the age of 30 to 50 years, it is often preceded by an upper respiratory tract infection and may be associated with inflammatory bowel disease and pregnancy.
  • Approximately one-third of patients with CSS experience recurrence of the dermatosis.
  • The malignancy-associated Sweet's syndrome (MASS) can occur as a paraneoplastic syndrome in patients with an established cancer or individuals whose Sweet's syndrome-related hematologic dyscrasia or solid tumor was previously undiscovered; MASS is most commonly related to acute myelogenous leukemia.
  • The dermatosis can precede, follow, or appear concurrent with the diagnosis of the patient's cancer.
  • Hence, MASS can be the cutaneous harbinger of either an undiagnosed visceral malignancy in a previously cancer-free individual or an unsuspected cancer recurrence in an oncology patient.
  • Drug-induced Sweet's syndrome (DISS) most commonly occurs in patients who have been treated with granulocyte-colony stimulating factor, however, other medications may also be associated with DISS.
  • Systemic corticosteroids are the therapeutic gold standard for Sweet's syndrome.
  • After initiation of treatment with systemic corticosteroids, there is a prompt response consisting of dramatic improvement of both the dermatosis-related symptoms and skin lesions.
  • Topical application of high potency corticosteroids or intralesional corticosteroids may be efficacious for treating localized lesions.
  • The symptoms and lesions of Sweet's syndrome may resolved spontaneously, without any therapeutic intervention; however, recurrence may follow either spontaneous remission or therapy-induced clinical resolution.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Neutrophilic dermatosis, acute febrile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1971 Jan;103(1):81-4 [5539508.001]
  • [Cites] Dermatologica. 1971;143(3):153-9 [5131096.001]
  • [Cites] Australas J Dermatol. 1971 Dec;12(3):172-7 [5146931.001]
  • [Cites] Arch Dermatol. 1975 Nov;111(11):1461-3 [1239237.001]
  • [Cites] Am J Med. 1976 Sep;61(3):424-32 [961707.001]
  • [Cites] J Rheumatol. 1977 Summer;4(2):201-6 [881698.001]
  • [Cites] S Afr Med J. 1978 Feb 18;53(7):253-6 [653521.001]
  • [Cites] South Med J. 1978 Nov;71(11):1350-2 [280960.001]
  • [Cites] Rev Prat. 1999 Feb 15;49(4):356-8 [10319682.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 2):838-41 [10321630.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):1174-5 [10354095.001]
  • [Cites] Am J Hematol. 1999 Jun;61(2):126-9 [10367792.001]
  • [Cites] Pediatr Cardiol. 1999 Jul-Aug;20(4):295-7 [10368458.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):247-52 [10380046.001]
  • [Cites] Pediatr Infect Dis J. 1999 Jun;18(6):568-70 [10391198.001]
  • [Cites] Br J Dermatol. 1999 Jul;141(1):169-70 [10417544.001]
  • [Cites] Arch Neurol. 1999 Aug;56(8):1010-3 [10448808.001]
  • [Cites] Br J Dermatol. 1964 Aug-Sep;76:349-56 [14201182.001]
  • [Cites] Br J Dermatol. 2004 Nov;151(5):1096-100 [15541094.001]
  • [Cites] Int J Dermatol. 2004 Dec;43(12):938-41 [15569025.001]
  • [Cites] Ann Rheum Dis. 2005 Jan;64(1):168-9 [15608327.001]
  • [Cites] J Am Acad Dermatol. 2005 Feb;52(2):367-9 [15692491.001]
  • [Cites] Orbit. 2005 Mar;24(1):55-7 [15764119.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):368-70 [15781678.001]
  • [Cites] Can J Ophthalmol. 2005 Feb;40(1):90-2 [15825540.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):901-5 [15858487.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):927-8 [15858502.001]
  • [Cites] Neurology. 2005 May 24;64(10):1756-61 [15911805.001]
  • [Cites] Hautarzt. 1988 Oct;39(10):658-61 [3069805.001]
  • [Cites] Am J Dermatopathol. 1989 Apr;11(2):99-111 [2653084.001]
  • [Cites] J Am Acad Dermatol. 1989 Apr;20(4):677-80 [2715414.001]
  • [Cites] J Am Acad Dermatol. 1989 Aug;21(2 Pt 2):339-43 [2526826.001]
  • [Cites] Am J Hematol. 1989 Oct;32(2):134-7 [2667344.001]
  • [Cites] Cutis. 1989 Aug;44(2):125-9 [2758862.001]
  • [Cites] Cutis. 1989 Aug;44(2):157-9 [2758865.001]
  • [Cites] Clin Exp Dermatol. 1988 Sep;13(5):344-6 [3256451.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1103-4 [17034566.001]
  • [Cites] Int J Dermatol. 2006 Oct;45(10):1254-5 [17040460.001]
  • [Cites] Int J Dermatol. 2006 Nov;45(11):1365-8 [17076728.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):1066-71 [17097401.001]
  • [Cites] Int J Dermatol. 2007 Jan;46(1):106-11 [17214733.001]
  • [Cites] Australas J Dermatol. 2007 Feb;48(1):50-3 [17222305.001]
  • [Cites] J Am Acad Dermatol. 2007 Feb;56(2 Suppl):S61-2 [17224394.001]
  • [Cites] Br J Dermatol. 2007 Mar;156(3):480-5 [17300237.001]
  • [Cites] Intern Med. 2007;46(4):153-4 [17301507.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):275-6 [17310019.001]
  • [Cites] Rev Med Liege. 2006 Dec;61(12):834-6 [17313120.001]
  • [Cites] Presse Med. 2007 Mar;36(3 Pt 1):419-24 [17321363.001]
  • [Cites] J Dermatol. 2007 Apr;34(4):243-7 [17352721.001]
  • [Cites] J Dermatol. 2007 Apr;34(4):258-61 [17352724.001]
  • [Cites] J Am Acad Dermatol. 2007 Apr;56(4):690-3 [17367621.001]
  • [Cites] Ann Dermatol Venereol. 2007 Feb;134(2):151-4 [17375012.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Actas Dermosifiliogr. 2007 Mar;98(2):102-4 [17397596.001]
  • [Cites] Am J Dermatopathol. 2007 Apr;29(2):125-33 [17414432.001]
  • [Cites] J Neurol. 2003 Jun;250(6):770-1 [12862039.001]
  • [Cites] Actas Dermosifiliogr. 2005 Jun;96(5):315-6 [16476395.001]
  • [Cites] Clin Exp Dermatol. 2006 Mar;31(2):206-7 [16487091.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S122-6 [16488324.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):235-40 [16490855.001]
  • [Cites] Korean J Intern Med. 2005 Dec;20(4):346-8 [16491836.001]
  • [Cites] Clin Rheumatol. 2006 Mar;25(2):268-72 [15902518.001]
  • [Cites] J Otolaryngol. 2006 Apr;35(2):144-7 [16527036.001]
  • [Cites] J Infect. 2006 May;52(5):e155-7 [16213026.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Apr;20(4):401-5 [16643136.001]
  • [Cites] Int J Dermatol. 2006 Jun;45(6):677-80 [16796626.001]
  • [Cites] Int J Dermatol. 2006 Jun;45(6):702-8 [16796632.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):1070-1 [16924066.001]
  • [Cites] Arch Dermatol. 2006 Sep;142(9):1170-6 [16983004.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):148 [16856884.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1089-90 [17034556.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1099-101 [17034564.001]
  • [Cites] J Am Acad Dermatol. 1998 Dec;39(6):940-3 [9843005.001]
  • [Cites] Br J Dermatol. 1998 Sep;139(3):555-6 [9767320.001]
  • [Cites] Eur J Dermatol. 1998 Oct-Nov;8(7):503-5 [9854164.001]
  • [Cites] Br J Dermatol. 1998 Oct;139(4):744-5 [9892926.001]
  • [Cites] Br J Dermatol. 1998 Nov;139(5):930-1 [9892977.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Dec;119(6):709-10 [9852556.001]
  • [Cites] Arch Dermatol. 1999 Jan;135(1):62-6 [9923783.001]
  • [Cites] J Rheumatol. 1999 Feb;26(2):440-2 [9972982.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):275-9 [10025763.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 2):331-4 [10025862.001]
  • [Cites] Cutis. 1999 Mar;63(3):177-9 [10190073.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):565-6 [10233302.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):341-3 [15223465.001]
  • [Cites] Ann Dermatol Venereol. 2004 Apr;131(4):369-72 [15258512.001]
  • [Cites] J Am Acad Dermatol. 2004 Sep;51(3):474-5 [15337997.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Nov;18(6):716-7 [15482306.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Nov;18(6):745-6 [15482319.001]
  • [Cites] Int J Dermatol. 2004 Oct;43(10):720-2 [15485526.001]
  • [Cites] Int J Dermatol. 2004 Oct;43(10):772-7 [15485540.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):396-9 [15491764.001]
  • [Cites] J Am Acad Dermatol. 1994 Apr;30(4):639-42 [8157792.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):415-7 [7515269.001]
  • [Cites] Clin Exp Dermatol. 1994 May;19(3):274-7 [8033398.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):645-8 [7519039.001]
  • [Cites] J Dermatol. 1994 May;21(5):341-6 [8051321.001]
  • [Cites] Int J Dermatol. 1994 Jun;33(6):425-32 [8056477.001]
  • [Cites] Acta Derm Venereol. 1994 May;74(3):229-30 [7915473.001]
  • [Cites] J Am Acad Dermatol. 1994 Oct;31(4):535-56; quiz 557-60 [8089280.001]
  • [Cites] Br J Dermatol. 1979 Jan;100(1):93-9 [427014.001]
  • [Cites] Dermatologica. 1980;160(5):341-7 [7364144.001]
  • [Cites] Br J Dermatol. 1981 Oct;105(4):483 [7295564.001]
  • [Cites] Postgrad Med. 1982 Jan;71(1):55-60 [7054779.001]
  • [Cites] S Afr Med J. 1982 Sep 4;62(11):375-8 [7112306.001]
  • [Cites] Clin Rheum Dis. 1982 Aug;8(2):427-41 [6754235.001]
  • [Cites] Br J Dermatol. 1983 Jan;108(1):99-101 [6821647.001]
  • [Cites] J Pediatr. 1983 Feb;102(2):243-8 [6822929.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1518-26 [6572088.001]
  • [Cites] Arch Dermatol. 1983 Jul;119(7):610-1 [6574727.001]
  • [Cites] J Am Acad Dermatol. 1983 Jul;9(1):77-81 [6886108.001]
  • [Cites] Cutis. 1983 Aug;32(2):152-4 [6617253.001]
  • [Cites] Arch Intern Med. 1983 Oct;143(10):1993-5 [6625786.001]
  • [Cites] Arch Neurol. 1983 Dec;40(13):829 [6639416.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):751-8 [6358279.001]
  • [Cites] Arch Dermatol. 1984 Feb;120(2):245-7 [6696481.001]
  • [Cites] Blut. 1984 May;48(5):297-305 [6722359.001]
  • [Cites] Arch Dermatol. 1985 Jun;121(6):789-91 [4004304.001]
  • [Cites] Dermatologica. 1985;171(2):102-5 [4043468.001]
  • [Cites] Presse Med. 1985 Sep 14;14(30):1599-601 [2995962.001]
  • [Cites] Lupus. 2005;14(5):399-402 [15934441.001]
  • [Cites] South Med J. 2005 May;98(5):570-2 [15954518.001]
  • [Cites] J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S135-8 [16021163.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):834-42 [16027297.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):881-4 [16027305.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):887-9 [16027306.001]
  • [Cites] Arch Dermatol. 2005 Jul;141(7):893-5 [16027307.001]
  • [Cites] Clin Dev Immunol. 2005 Jun;12(2):145-9 [16050146.001]
  • [Cites] Int J Dermatol. 2005 Aug;44(8):677-80 [16101872.001]
  • [Cites] Retina. 2005 Sep;25(6):800-2 [16141877.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):597-9 [16164716.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):634-7 [16164726.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):142 [16197442.001]
  • [Cites] Digestion. 2005;72(2-3):195-200 [16179788.001]
  • [Cites] Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):376-9 [16268426.001]
  • [Cites] Ann Dermatol Venereol. 2005 Nov;132(11 Pt 1):883-5 [16327718.001]
  • [Cites] Int J Dermatol. 2005 Nov;44(11):946-7 [16336530.001]
  • [Cites] Pediatr Dermatol. 2005 Nov-Dec;22(6):525-9 [16354254.001]
  • [Cites] Pediatr Dermatol. 2005 Nov-Dec;22(6):530-5 [16354255.001]
  • [Cites] J Indian Med Assoc. 2005 Aug;103(8):433-5 [16363199.001]
  • [Cites] J Assoc Physicians India. 2005 Aug;53:728-30 [16398086.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):364 [16157374.001]
  • [Cites] Int J Dermatol. 2005 Dec;44(12):1051-3 [16409276.001]
  • [Cites] Arch Dermatol. 2006 Jan;142(1):57-63 [16415387.001]
  • [Cites] Int J Dermatol. 2006 Jan;45(1):51-2 [16426377.001]
  • [Cites] Int J Dermatol. 2006 Jan;45(1):70-80 [16426383.001]
  • [Cites] Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):1003-6 [16446647.001]
  • [Cites] Haematologica. 2005 Dec;90(12 Suppl):ECR43 [16464758.001]
  • [Cites] South Med J. 2007 Oct;100(10):1057-8 [17943059.001]
  • [Cites] Pediatrics. 1999 Nov;104(5 Pt 1):1142-4 [10545563.001]
  • [Cites] Clin Exp Dermatol. 1999 Sep;24(5):368-71 [10564323.001]
  • [Cites] Australas J Dermatol. 1999 Nov;40(4):204-7 [10570557.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1887-97 [3058878.001]
  • [Cites] J Am Acad Dermatol. 1988 Dec;19(6):983-1005 [3060489.001]
  • [Cites] Am Fam Physician. 1989 Mar;39(3):199-204 [2646883.001]
  • [Cites] Ann Intern Med. 1989 Apr 1;110(7):573-4 [2923392.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):334-59 [9208889.001]
  • [Cites] J Am Acad Dermatol. 1997 Jul;37(1):123-4 [9216537.001]
  • [Cites] Clin Exp Dermatol. 1997 Jan;22(1):54-6 [9330058.001]
  • [Cites] Int J Dermatol. 1997 Sep;36(9):717-8 [9352420.001]
  • [Cites] Br J Dermatol. 1997 Oct;137(4):609-13 [9390341.001]
  • [Cites] Thorac Cardiovasc Surg. 1997 Oct;45(5):247-8 [9402666.001]
  • [Cites] Med Clin (Barc). 1997 Nov 1;109(15):588-91 [9441195.001]
  • [Cites] Int J Dermatol. 1997 Nov;36(11):837-44 [9427076.001]
  • [Cites] Br J Dermatol. 1989 Sep;121(3):413-5 [2803964.001]
  • [Cites] J Pediatr. 1989 Nov;115(5 Pt 1):726-9 [2809903.001]
  • [Cites] J Pediatr. 1989 Nov;115(5 Pt 1):730-4 [2809904.001]
  • [Cites] Vestn Dermatol Venerol. 1989;(11):67-9 [2618175.001]
  • [Cites] Neth J Med. 1990 Feb;36(1-2):62-8 [2278538.001]
  • [Cites] J Rheumatol. 1990 May;17(5):682-4 [2193156.001]
  • [Cites] Rev Clin Esp. 1990 Apr;186(6):264-9 [2203115.001]
  • [Cites] Am J Med. 1990 Sep;89(3):396 [2203266.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):247-9 [2212120.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):503-7 [2212153.001]
  • [Cites] Int J Dermatol. 1990 Dec;29(10):737 [2269574.001]
  • [Cites] Acta Haematol. 1990;84(4):207-8 [2125789.001]
  • [Cites] Dermatologica. 1991;182(1):43-6 [1826487.001]
  • [Cites] Br J Dermatol. 1991 Apr;124(4):348-53 [2025555.001]
  • [Cites] J R Soc Med. 1991 May;84(5):307-8 [2041012.001]
  • [Cites] Acta Derm Venereol. 1991;71(1):77-9 [1676226.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):858-60 [2099706.001]
  • [Cites] Australas J Dermatol. 1991;32(1):55-9 [1834046.001]
  • [Cites] Am J Med. 1991 Nov;91(5):553-4 [1951419.001]
  • [Cites] Dermatologica. 1991;183(3):230-3 [1743390.001]
  • [Cites] Acta Derm Venereol. 2003;83(4):290-1 [12926802.001]
  • [Cites] Br J Dermatol. 2003 Sep;149(3):675-7 [14511020.001]
  • [Cites] Int J Dermatol. 2003 Oct;42(10):761-78 [14521689.001]
  • [Cites] Med Clin (Barc). 2003 Oct 4;121(11):437 [14563281.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):907-9 [14576675.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1374 [14585639.001]
  • [Cites] Korean J Intern Med. 2003 Sep;18(3):187-90 [14619389.001]
  • [Cites] Br J Dermatol. 2003 Oct;149(4):884 [14616386.001]
  • [Cites] Contact Dermatitis. 2003 Jul;49(1):42 [14641120.001]
  • [Cites] J Cutan Pathol. 2004 Jan;31(1):72-6 [14675289.001]
  • [Cites] J Cutan Pathol. 2004 Feb;31(2):189-94 [14690466.001]
  • [Cites] Int J Dermatol. 2004 Jan;43(1):57-9 [14693024.001]
  • [Cites] QJM. 2004 Jan;97(1):55-6 [14702513.001]
  • [Cites] J Am Acad Dermatol. 2004 Feb;50(2):280-5 [14726888.001]
  • [Cites] Clin Nucl Med. 2004 Feb;29(2):91-2 [14734904.001]
  • [Cites] Eye (Lond). 2004 Feb;18(2):214; discussion 214-6 [14762428.001]
  • [Cites] J Laryngol Otol. 2004 Jan;118(1):48-9 [14979973.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Mar;18(2):233 [15009320.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S61-3 [15036943.001]
  • [Cites] Dermatology. 2004;208(2):175 [15057014.001]
  • [Cites] J Fam Plann Reprod Health Care. 2004 Apr;30(2):115-6 [15086998.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5 Suppl):S90-2 [15097938.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):798-9 [15097971.001]
  • [Cites] Int J Dermatol. 2004 Feb;43(2):95-102 [15125498.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):197-9 [15125614.001]
  • [Cites] Arch Dermatol. 2004 May;140(5):570-4 [15148101.001]
  • [Cites] J Med Assoc Thai. 2004 May;87(5):567-72 [15222531.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):283-5 [15224368.001]
  • [Cites] Br J Haematol. 1993 Sep;85(1):191-2 [7504506.001]
  • [Cites] Dermatology. 1993;187(4):303-5 [8274797.001]
  • [Cites] Acta Derm Venereol. 1993 Oct;73(5):380-1 [7904408.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):293-7 [8294584.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):297-300 [8294585.001]
  • [Cites] J Cutan Pathol. 1993 Oct;20(5):465-78 [7507948.001]
  • [Cites] Clin Exp Dermatol. 1994 Jan;19(1):51-2 [8313637.001]
  • [Cites] South Med J. 1994 Feb;87(2):193-6 [8115882.001]
  • [Cites] Int J Dermatol. 2001 Dec;40(12):791-3 [11903682.001]
  • [Cites] Ann Hematol. 2002 Feb;81(2):111-4 [11907794.001]
  • [Cites] Acta Orthop Belg. 2002 Feb;68(1):68-71 [11915462.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Mar;26(3):295-7 [11981477.001]
  • [Cites] Int J Dermatol. 2002 Feb;41(2):107-9 [11982648.001]
  • [Cites] Clin Pediatr (Phila). 2002 Apr;41(3):175-7 [11999681.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):1087-90 [12072085.001]
  • [Cites] J Occup Environ Med. 2002 Jun;44(6):491-2 [12085472.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1596 [8090038.001]
  • [Cites] Am Fam Physician. 1994 Nov 1;50(6):1273-82 [7942426.001]
  • [Cites] J Am Acad Dermatol. 1994 Dec;31(6):1045-7 [7962753.001]
  • [Cites] Pediatr Dermatol. 1994 Sep;11(3):237-40 [7971558.001]
  • [Cites] J Rheumatol. 1994 Sep;21(9):1766-8 [7799365.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):192-8 [7829702.001]
  • [Cites] Mayo Clin Proc. 1995 Mar;70(3):234-40 [7861810.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):261-4 [7532508.001]
  • [Cites] J Am Acad Dermatol. 1995 Mar;32(3):533-5 [7868739.001]
  • [Cites] Int J Dermatol. 1995 Jan;34(1):73-4 [7896497.001]
  • [Cites] Australas J Dermatol. 1994;35(2):91-2 [7702496.001]
  • [Cites] Dermatology. 1995;190(2):160-3 [7727840.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):687-90 [7774902.001]
  • [Cites] Mayo Clin Proc. 1995 Jun;70(6):605-6 [7632268.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):144-5 [7601939.001]
  • [Cites] Int J Dermatol. 1995 May;34(5):323-9 [7607792.001]
  • [Cites] Am J Med. 1995 Aug;99(2):207-16 [7625426.001]
  • [Cites] Semin Dermatol. 1995 Jun;14(2):173-8 [7640199.001]
  • [Cites] Postgrad Med J. 1995 Jun;71(836):383 [7644412.001]
  • [Cites] Acta Derm Venereol. 1995 May;75(3):237-9 [7653187.001]
  • [Cites] Pediatr Dermatol. 1985 Nov;3(1):40-4 [3906610.001]
  • [Cites] Dermatol Clin. 1985 Jan;3(1):153-63 [3912087.001]
  • [Cites] Cutis. 1986 Mar;37(3):167-74 [3514153.001]
  • [Cites] Am J Med. 1986 Sep;81(3):558-60 [2944382.001]
  • [Cites] Dermatologica. 1986;173(2):85-9 [3792603.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):251, 254 [2434033.001]
  • [Cites] J Clin Pathol. 1987 Feb;40(2):175-9 [3546396.001]
  • [Cites] Am J Med. 1987 Jun;82(6):1220-6 [3300306.001]
  • [Cites] Cutis. 1987 Aug;40(2):139-42 [3621997.001]
  • [Cites] J Assoc Physicians India. 2002 Oct;50:1322-3 [12568224.001]
  • [Cites] Dermatology. 2003;206(2):81-4 [12592072.001]
  • [Cites] J Cutan Pathol. 2003 Apr;30(4):261-4 [12680958.001]
  • [Cites] Int J Dermatol. 2003 Jun;42(6):438-43 [12786869.001]
  • [Cites] Clin Exp Dermatol. 2003 Jul;28(4):377-9 [12823297.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1):132-8 [12833027.001]
  • [Cites] Ann Acad Med Singapore. 2003 May;32(3):411-4 [12854387.001]
  • [Cites] Clin Exp Dermatol. 1987 Sep;12(5):345-9 [3446421.001]
  • [Cites] Tunis Med. 2007 Jan;85(1):49-53 [17424710.001]
  • [Cites] South Med J. 2007 Apr;100(4):414-5 [17458409.001]
  • [Cites] Ann Pharmacother. 2007 May;41(5):802-11 [17426076.001]
  • [Cites] Int J Dermatol. 2007 May;46(5):496-9 [17472681.001]
  • [Cites] Clin Rheumatol. 2007 Jul;26(7):1215-6 [17294051.001]
  • [Cites] Australas J Dermatol. 2007 May;48(2):105-9 [17535199.001]
  • [Cites] Int J Dermatol. 2007 Jun;46(6):571-4 [17550553.001]
  • [Cites] Clin Dermatol. 2007 May-Jun;25(3):326-33 [17560310.001]
  • [Cites] J Cutan Pathol. 2007 Jul;34(7):526-34 [17576331.001]
  • [Cites] Ann Hematol. 2007 Aug;86(8):613-4 [17468870.001]
  • [Cites] Med Sci Monit. 2007 Apr;13(4):CS53-5 [17392656.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):989-90 [8959963.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):995-7 [8959967.001]
  • [Cites] Arch Dermatol. 1996 Dec;132(12):1507, 1510 [8961884.001]
  • [Cites] Br J Dermatol. 1997 Jan;136(1):142-4 [9039324.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):296-7 [9068763.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):436-9 [9091476.001]
  • [Cites] Dermatology. 1997;194(2):182-4 [9094473.001]
  • [Cites] Int J Dermatol. 1997 Apr;36(4):292-3 [9169331.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):135-6 [12461805.001]
  • [Cites] Ann Rheum Dis. 2003 Jan;62(1):81-2 [12480678.001]
  • [Cites] Int J Dermatol. 2002 Dec;41(12):928-30 [12492993.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):101-2 [12533182.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):102 [12533183.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1033-4 [10570395.001]
  • [Cites] Br J Ophthalmol. 1998 Mar;82(3):328-9 [9602638.001]
  • [Cites] Br J Dermatol. 1998 Feb;138(2):365-6 [9602899.001]
  • [Cites] Clin Exp Dermatol. 1997 Nov;22(6):269-73 [9604452.001]
  • [Cites] Australas J Dermatol. 1998 May;39(2):116-8 [9611384.001]
  • [Cites] Dermatology. 1998;196(3):346-7 [9621146.001]
  • [Cites] Eur Respir J. 1998 Apr;11(4):978-80 [9623707.001]
  • [Cites] Am J Hematol. 1998 Aug;58(4):337-8 [9692401.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):178-81 [9722904.001]
  • [Cites] Br J Dermatol. 1998 Jul;139(1):107-10 [9764159.001]
  • [Cites] Ann Hematol. 1998 Sep;77(3):135-8 [9797084.001]
  • [Cites] Dermatology. 1998;197(2):195-6 [9840982.001]
  • [Cites] Intensive Care Med. 1998 Oct;24(10):1106-9 [9840248.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):766-7 [10583147.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):943-4 [10583195.001]
  • [Cites] J Clin Gastroenterol. 1999 Dec;29(4):349-50 [10599643.001]
  • [Cites] Clin Exp Dermatol. 1999 Nov;24(6):443-5 [10606943.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):83-6 [10634651.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 2):332-4 [10640926.001]
  • [Cites] Am J Med. 2000 Apr 1;108(5):434-5 [10759106.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Apr;89(4):477-9 [10760730.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 2):932-5 [10767709.001]
  • [Cites] Arch Dermatol. 2000 May;136(5):673-4 [10815868.001]
  • [Cites] Australas J Dermatol. 1991;32(2):61-4 [1781756.001]
  • [Cites] J Am Acad Dermatol. 1991 Oct;25(4):734 [1724249.001]
  • [Cites] Arthritis Rheum. 1992 Apr;35(4):484-6 [1567500.001]
  • [Cites] Dermatologica. 1991;183(4):255-64 [1809587.001]
  • [Cites] Ann Intern Med. 1992 Jun 15;116(12 Pt 1):996-8 [1375012.001]
  • [Cites] J Rheumatol. 1992 May;19(5):814-20 [1613717.001]
  • [Cites] Am Rev Respir Dis. 1992 Jul;146(1):269 [1626811.001]
  • [Cites] Cutis. 1992 Jun;49(6):448-50 [1628515.001]
  • [Cites] Intern Med. 1992 May;31(5):686-9 [1504437.001]
  • [Cites] Aust N Z J Ophthalmol. 1992 Aug;20(3):263-5 [1449782.001]
  • [Cites] Int J Dermatol. 1992 Sep;31(9):670-1 [1459771.001]
  • [Cites] Acta Haematol. 1992;88(2-3):154-7 [1466198.001]
  • [Cites] Br J Dermatol. 1992 Nov;127(5):538-9 [1467297.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 2):801-4 [1469130.001]
  • [Cites] Pediatr Dermatol. 1992 Sep;9(3):288-92 [1488383.001]
  • [Cites] Clin Exp Dermatol. 1993 Jan;18(1):47-9 [8440052.001]
  • [Cites] Cutis. 1993 Mar;51(3):175-9 [8444048.001]
  • [Cites] Cutis. 1993 Feb;51(2):112-4 [8453891.001]
  • [Cites] Int J Dermatol. 1993 Apr;32(4):261-8 [8486457.001]
  • [Cites] Arch Ophthalmol. 1993 May;111(5):587-8 [8489431.001]
  • [Cites] Mayo Clin Proc. 1993 Jun;68(6):620-1 [8497142.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):584-6 [8504055.001]
  • [Cites] Clin Dermatol. 1993 Jan-Mar;11(1):149-57 [8339190.001]
  • [Cites] Arch Dermatol. 1993 Aug;129(8):1062-4 [8352617.001]
  • [Cites] Obstet Gynecol Surv. 1993 Aug;48(8):584-7 [8371901.001]
  • [Cites] Br J Haematol. 1993 Jun;84(2):356-8 [7691149.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2723-31 [8402496.001]
  • [Cites] Australas J Dermatol. 1993;34(1):31-3 [8240185.001]
  • [Cites] Korean J Intern Med. 2001 Sep;16(3):218-21 [11769583.001]
  • [Cites] Dermatology. 2002;204(1):84 [11834860.001]
  • [Cites] J Dermatol. 2002 Feb;29(2):91-5 [11890302.001]
  • [Cites] Am J Clin Dermatol. 2002;3(2):117-31 [11893223.001]
  • [Cites] Int J Dermatol. 2002 Jan;41(1):28-31 [11895510.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):345-9 [11902985.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):361-5 [11902987.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):400-3 [11902994.001]
  • [Cites] Clin Dermatol. 2000 May-Jun;18(3):265-82 [10856659.001]
  • [Cites] Arch Intern Med. 2000 Jun 26;160(12):1869 [10871983.001]
  • [Cites] Acta Derm Venereol. 2000 Mar-Apr;80(2):145-6 [10877140.001]
  • [Cites] Eur J Haematol. 2000 Jul;65(1):72-3 [10914942.001]
  • [Cites] Br J Dermatol. 2000 Aug;143(2):449-50 [10951165.001]
  • [Cites] J Am Acad Dermatol. 2000 Oct;43(4):691-7 [11004629.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):429-33 [11048979.001]
  • [Cites] Postgrad Med J. 2000 Nov;76(901):713-4 [11060149.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):914-6 [11069494.001]
  • [Cites] Int J Dermatol. 2000 Oct;39(10):795-8 [11095204.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1322-4 [11122045.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):59-62 [11196274.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):870-4 [11050599.001]
  • [Cites] J Cutan Pathol. 2001 Feb;28(2):90-6 [11168757.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):862-4 [11312438.001]
  • [Cites] Medicine (Baltimore). 2001 May;80(3):173-9 [11388093.001]
  • [Cites] Acta Derm Venereol. 2001 Jan-Feb;81(1):73-4 [11411932.001]
  • [Cites] Am J Med. 2001 Jul;111(1):80-1 [11460854.001]
  • [Cites] J Am Acad Dermatol. 2001 Aug;45(2):300-2 [11464196.001]
  • [Cites] J Neurol Sci. 2001 Jul 15;188(1-2):95-7 [11489291.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1106-8 [11493115.001]
  • [Cites] Yale J Biol Med. 2001 May-Jun;74(3):165-8 [11501712.001]
  • [Cites] J Am Acad Dermatol. 2001 Sep;45(3):325-61; quiz 362-4 [11511831.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):590-5 [11568752.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1526-9 [11598485.001]
  • [Cites] Clin Exp Dermatol. 2001 Nov;26(8):668-70 [11722452.001]
  • [Cites] Dermatology. 1995;190(4):335-7 [7655121.001]
  • [Cites] J Am Acad Dermatol. 1995 Sep;33(3):393-410; quiz 410-2 [7544812.001]
  • [Cites] Clin Exp Dermatol. 1995 May;20(3):279-80 [7671433.001]
  • [Cites] Arch Dermatol. 1995 Oct;131(10):1175-7 [7574835.001]
  • [Cites] Aust Fam Physician. 1995 Oct;24(10):1867-9 [8546614.001]
  • [Cites] Am J Med. 1995 Dec;99(6):662-71 [7503090.001]
  • [Cites] Br J Dermatol. 1995 Sep;133(3):483-6 [8547011.001]
  • [Cites] Br J Dermatol. 1995 Sep;133(3):490-1 [8547013.001]
  • [Cites] Lancet. 1996 Mar 9;347(9002):690 [8596402.001]
  • [Cites] J Am Acad Dermatol. 1996 Mar;34(3):539 [8609279.001]
  • [Cites] Pediatrics. 1996 Mar;97(3):401-3 [8604280.001]
  • [Cites] Leukemia. 1996 Apr;10(4):731-4 [8618455.001]
  • [Cites] J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23 [8621829.001]
  • [Cites] Cutis. 1996 Feb;57(2):107-10 [8646854.001]
  • [Cites] Adv Dermatol. 1996;11:215-52; discussion 253 [8718480.001]
  • [Cites] Australas J Dermatol. 1996 May;37(2):99-101 [8687337.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Mar;32B(2):133-6 [8736177.001]
  • [Cites] Br J Dermatol. 1996 Apr;134(4):705-9 [8733376.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):282-4 [8689342.001]
  • [Cites] Clin Exp Dermatol. 1996 Mar;21(2):175 [8759219.001]
  • [Cites] Am J Med. 1996 Aug;101(2):231-3 [8757366.001]
  • [Cites] Ann Acad Med Singapore. 1996 Mar;25(2):222-7 [8799010.001]
  • [Cites] J Neurol. 1996 Jul;243(7):556-7 [8836949.001]
  • [Cites] Int J Dermatol. 1996 Jan;35(1):9-15 [8838921.001]
  • [Cites] Respir Med. 1996 Jan;90(1):57-9 [8857328.001]
  • [Cites] J Am Acad Dermatol. 1996 Oct;35(4):629-31 [8859296.001]
  • [Cites] Haematologica. 1996 Jan-Feb;81(1):54-8 [8900854.001]
  • [Cites] J Rheumatol. 1996 Nov;23(11):1995-8 [8923382.001]
  • [Cites] J Cutan Pathol. 2002 May;29(5):301-4 [12100632.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):323-4 [12140489.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):397-8 [12185512.001]
  • [Cites] Br J Dermatol. 2002 Sep;147(3):558-62 [12207601.001]
  • [Cites] Rheumatology (Oxford). 2002 Sep;41(9):1067-9 [12209043.001]
  • [Cites] Acta Derm Venereol. 2002;82(3):221 [12353722.001]
  • [Cites] Am J Psychiatry. 2002 Nov;159(11):1947 [12411238.001]
  • [Cites] Eur J Radiol. 2002 Nov;44(2):139-42 [12413682.001]
  • (PMID = 17655751.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 435
  • [Other-IDs] NLM/ PMC1963326
  •  go-up   go-down


7. Yoshida C, Kojima H, Iijima T, Katsura Y, Shimizu S, Suzukawa K, Mukai HY, Hasegawa Y, Abei M, Nagasawa T: Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia. Eur J Haematol; 2004 Mar;72(3):225-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia.
  • A 54-yr-old female having chronic neutrophilic leukemia (CNL) associated with severe liver injury is presented.
  • Complete blood count showed a hemoglobin level of 9.1 g/dL, platelet count of 25.8 x 10(4)/microL, and white blood cell count of 36.6 x 10(3)/microL with 89.7% neutrophils.
  • Blood chemistry showed hyperbilirubinemia (21.9 mg/dL) with normal transaminase levels.
  • There was no abnormality in serum cholesterol, triglyceride, or glucose levels.
  • Neutrophil alkaline phosphatase activity was significantly elevated.
  • Rearrangement of the bcr/abl was not detected by either polymerase chain reaction or fluorescence in situ hybridization.
  • Human androgen receptor gene assay (HUMARA) of the bone marrow cells showed clonal proliferation of neutrophils.
  • As the patient had no history of alcohol abuse, a diagnosis of non-alcoholic steatohepatitis (NASH) was made.
  • Assuming that the infiltration of abnormal neutrophils into the liver contributed to the development of NASH, she was treated with cytoreductive chemotherapy (cytosine arabinoside: 100 mg/d, 1-3 doses/wk).
  • With decreases in white blood cell counts, serum bilirubin levels decreased gradually to 1.5 mg/mL.
  • To our knowledge, this is the first report describing the development of NASH in a myeloproliferative disorder.
  • [MeSH-major] Fatty Liver / etiology. Leukemia, Neutrophilic, Chronic / complications
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Cytarabine / therapeutic use. Female. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • Genetic Alliance. consumer health - Non-alcoholic steatohepatitis (NASH).
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14962243.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


8. Piliotis E, Kutas G, Lipton JH: Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia. Leuk Lymphoma; 2002 Oct;43(10):2051-4
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia.
  • Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder characterized by a clonal proliferation of mainly mature neutrophils, which is often difficult to differentiate from reactive leukocytosis or other myeloproliferative disorders.
  • Treatment to date has focused on disease control rather than cure.
  • Once the disease has progressed to a more aggressive leukemia there is typically little chance of obtaining a long lasting remission due to the older age of most patients as well as the acquisition of multiple poor prognostic cytogenetic abnormalities.
  • In this case report we describe a successful sibling allogeneic bone marrow transplant in a 60-year-old man with CNL performed while he was still in the stable phase of his disease.
  • We propose that even in older patients this curative approach may be considered in selected patients at an early stage of their disease, similar to the approach taken with chronic myelogenous leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Neutrophilic, Chronic / therapy
  • [MeSH-minor] Disease Management. Disease-Free Survival. Graft Survival. Graft vs Host Disease / drug therapy. Humans. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12481908.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Telek B, Batár P, Udvardy M, László R: [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature]. Orv Hetil; 2006 May 7;147(18):827-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature].
  • Chronic neutrophilic leukemia is an uncommon hematological entity.
  • In the last 20 years seven patients have been diagnosed with chronic neutrophilic leukemia at our department.
  • All but one had splenomegaly, two patients developed severe anaemia and in one case thrombocytosis was present at the time of diagnosis.
  • White blood cell count ranged between 39 x 10(9)/1-71 x 10(9)/l with 80% of neutrophils and striking myeloid hyperplasia were present in the bone marrow without evidence of any dysplasia resembling chronic myelocytic leukemia.
  • Granulocyte alkaline phosphatase scores were increased except one case and both cytogenetics (Philadelphia chromosome) and molecular biologic analysis (bcr/abl) revealed no alteration of any.
  • Three of them died due to progression of chronic neutrophilic leukemia.
  • One patient, initially receiving hydroxyurea + interferon therapy and showing progression, developed complete hematological remission with an eight week imatinib mesylate (Glivec) treatment.
  • Beside of their own experiences the authors review the current literature and discuss differential diagnostic and therapeutic challenges, as well.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Neutrophilic, Chronic / diagnosis. Leukemia, Neutrophilic, Chronic / drug therapy
  • [MeSH-minor] Aged. Benzamides. Diagnosis, Differential. Humans. Hungary. Hydroxyurea / administration & dosage. Imatinib Mesylate. Interferons / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Male. Middle Aged. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Retrospective Studies. Splenomegaly / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Neutrophilic Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784137.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; 9008-11-1 / Interferons; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


10. Srivastava M, Scharf S, Meehan SA, Polsky D: Neutrophilic eccrine hidradenitis masquerading as facial cellulitis. J Am Acad Dermatol; 2007 Apr;56(4):693-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis masquerading as facial cellulitis.
  • Neutrophilic eccrine hidradenitis typically manifests as erythematous plaques on the face, trunk, or extremities.
  • This eruption has been associated with numerous factors, but most commonly is seen with chemotherapy, particularly cytarabine.
  • We report a 73-year-old woman with acute myelogenous leukemia who developed rapidly expansive neutrophilic eccrine hidradenitis mimicking facial cellulitis only after a course of cytarabine was followed by granulocyte-colony stimulating factor.
  • Prompt diagnosis is imperative to prevent prolonged antimicrobial therapy.
  • [MeSH-major] Cellulitis / pathology. Cytarabine / adverse effects. Facial Dermatoses / pathology. Hidradenitis / chemically induced. Hidradenitis / pathology. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Idarubicin / adverse effects. Idarubicin / therapeutic use. Immunohistochemistry. Risk Assessment

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cellulitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109994.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


11. Gómez Vázquez M, Peteiro C, Toribio J: Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia. J Eur Acad Dermatol Venereol; 2003 May;17(3):328-30
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis heralding the onset of chronic myelogenous leukaemia.
  • Neutrophilic eccrine hidradenitis was initially described in acute myelogenous leukaemic patients undergoing chemotherapy, suggesting a drug-induced mechanism.
  • However, most the reported cases have been described in acute myelogenous leukaemic cases receiving chemotherapy.
  • We describe a neutrophilic eccrine hidradenitis case unassociated with chemotherapy in a woman with chronic myelogenous leukaemia.
  • [MeSH-major] Hidradenitis / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Axilla. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12702078.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Itzykson R, Ayari S, Vassilief D, Berger E, Slama B, Vey N, Suarez F, Beyne-Rauzy O, Guerci A, Cheze S, Thomas X, Stamatoullas A, Gardembas M, Bauduer F, Kolb A, Chaury MC, Legros L, Damaj G, Chermat F, Dreyfus F, Fenaux P, Ades L, Groupe Francophone des Myelodysplasies (GFM): Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. Leukemia; 2009 Apr;23(4):673-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of anemia in lower risk myelodysplastic syndromes (MDS) without 5q deletion.
  • We conducted a prospective multicenter study of EPO-beta and ATRA in anemic MDS patients with marrow blasts <10% and either previous ESA failure or relapse, endogenous EPO >500 U/l or other cytopenia(s) (absolute neutrophilic count <1.0 G/l or platelets <50 G/l).
  • A total of 59 patients were evaluable after 12 weeks of treatment.
  • The erythroid response rates according to IWG 2000 and 2006 criteria, respectively, were as follows: overall: 49 and 36%; patients with previous ESA failure (n=28): 43 and 32%; patients with endogenous EPO >500 U/l (n=18): 11 and 19%; patients transfused >2 red blood cells units/month (n=28) 43 and 39%.
  • Only one neutrophil, but no platelet response, and no major side effect were observed.
  • EPO-beta-ATRA combination appears a possible therapeutic option in anemia of MDS having failed an ESA alone, but not in patients with high endogenous EPO level, and does not improve neutropenia and thrombocytopenia.
  • [MeSH-major] Erythropoietin / therapeutic use. Myelodysplastic Syndromes / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Therapy, Combination. Female. Humans. Leukocyte Count. Male. Middle Aged. Neutropenia / drug therapy. Neutrophils. Platelet Count. Recombinant Proteins. Thrombocytopenia / drug therapy. Treatment Outcome. Young Adult


13. Uhara H, Saida T, Nakazawa H, Ito T: Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor. J Am Acad Dermatol; 2008 Aug;59(2 Suppl 1):S10-2
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor.
  • We report a case of acute myeloid leukemia with folliculitis, Sweet's syndrome, and neutrophilic panniculitis after remission induction chemotherapy for acute myeloid leukemia.
  • The level of endogenous granulocyte colony-stimulating factor was closely associated with disease activity.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / blood. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / metabolism. Sweet Syndrome / complications. Sweet Syndrome / metabolism
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Folliculitis / complications. Folliculitis / metabolism. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625369.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; ZRP63D75JW / Idarubicin
  •  go-up   go-down


14. Inuzuka M, Tokura Y: Sterile suppurative folliculitis associated with acute myeloblastic leukaemia. Br J Dermatol; 2002 May;146(5):904-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sterile suppurative folliculitis associated with acute myeloblastic leukaemia.
  • A 20-year-old woman presented with a 4-month history of follicular papules distributed over the trunk and extremities.
  • One month later, routine blood tests were abnormal, showing acute myeloblastic leukaemia (M1 in the French-American-British classification).
  • Skin biopsy demonstrated a dermal infiltrate of a large number of neutrophils with occasional eosinophils and histiocytes in the vicinity of the hair follicle remnants.
  • The follicular eruption improved promptly in response to chemotherapy for the leukaemia.
  • We suggest that this case may represent a rare, follicular variant of neutrophilic dermatosis associated with myelogenous leukaemia.
  • [MeSH-major] Folliculitis / etiology. Leukemia, Myeloid, Acute / complications. Sweet Syndrome / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000394.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Murata-Ohsawa M, Tohda S, Kogoshi H, Sakano S, Nara N: The Notch ligand, Delta-1, alters retinoic acid (RA)-induced neutrophilic differentiation into monocytic and reduces RA-induced apoptosis in NB4 cells. Leuk Res; 2005 Feb;29(2):197-203
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Notch ligand, Delta-1, alters retinoic acid (RA)-induced neutrophilic differentiation into monocytic and reduces RA-induced apoptosis in NB4 cells.
  • NB4, an acute promyelocytic leukemia (APL) cell line, undergoes neutrophilic differentiation and apoptosis by RA.
  • Notch activation induced by a recombinant Notch ligand, Delta-1, did not affect the growth by itself.
  • Treatment with RA plus Delta-1 made part of NB4 cells monocyte-like shaped and reduced the apoptosis.
  • Similar phenomenon was also observed in primary APL cells.
  • RA treatment induced cleavage of caspase-8 and PARP in NB4.
  • [MeSH-major] Apoptosis / drug effects. Cell Differentiation / drug effects. Membrane Proteins / metabolism. Membrane Proteins / pharmacology. Neutrophils / cytology. Tretinoin / antagonists & inhibitors
  • [MeSH-minor] Antigens, CD / metabolism. Caspase 8. Caspases / drug effects. Caspases / metabolism. Cell Line, Tumor. Cell Lineage / drug effects. Flow Cytometry. Humans. Intracellular Signaling Peptides and Proteins. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Ligands. Monocytes / physiology. Poly(ADP-ribose) Polymerases / drug effects. RNA, Messenger / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, Macrophage Colony-Stimulating Factor / genetics. Receptors, Notch

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2005 Feb;29(2):127-9 [15607358.001]
  • (PMID = 15607369.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ligands; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Notch; 0 / delta protein; 5688UTC01R / Tretinoin; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  •  go-up   go-down


16. Thuillier D, Lenglet A, Chaby G, Royer R, Vaida I, Viseux V, Dadban A, Billet A, Christophe O, Chatelain D, Marolleau JP, Lok C, Damaj G: [Bortezomib-induced eruption: Sweet syndrome? Two case reports]. Ann Dermatol Venereol; 2009 May;136(5):427-30
Hazardous Substances Data Bank. COLCHICINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
  • [Transliterated title] Toxidermie au bortézomib : syndrome de Sweet? Deux cas.
  • BACKGROUND: Bortezomib (Velcade) is a proteasome inhibitor used in the treatment of myeloma and other blood dyscrasias.
  • We report the cases of two patients who developed a peculiar toxic rash suggestive of Sweet's syndrome while receiving bortezomib; one patient also presented giant mucous membrane ulcerations.
  • PATIENTS AND METHODS: Case 1: bortezomib treatment was started in a 62-year-old man for mantle cell lymphoma.
  • Ten days after the first treatment cycle, giant, painful oral ulcerations were noted but they resolved spontaneously.
  • One week after the second cycle, further oral ulceration appeared, this time with a papulonodular skin rash.
  • Histology showed neutrophilic dermal infiltrates in the skin with predominantly lymphocytic inflammation of the oral mucosa.
  • Bortezomib was stopped and all lesions resolved with colchicine treatment.
  • Case 2: a 46-year-old woman was receiving bortezomib treatment for plasma cell leukemia.
  • A febrile skin rash appeared two days after the first treatment cycle but resolved spontaneously.
  • DISCUSSION: Bortezomib-induced skin lesions are common and usually do not justify treatment withdrawal.
  • In our cases, these could be related to bortezomib-induced neutrophilic dermatosis.
  • [MeSH-minor] Biopsy. Bortezomib. Colchicine / therapeutic use. Dexamethasone / therapeutic use. Female. Humans. Leukemia, Plasma Cell / etiology. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Skin Ulcer / chemically induced. Skin Ulcer / pathology. Treatment Outcome

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442799.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; SML2Y3J35T / Colchicine
  •  go-up   go-down


17. Jacobson S, Martin DB, Deng A, Cooper JZ: Pyoderma gangrenosum following tattoo placement in a patient with acute myelogenous leukemia. J Dermatolog Treat; 2008;19(1):58-60
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyoderma gangrenosum following tattoo placement in a patient with acute myelogenous leukemia.
  • A 37-year-old African American female with a diagnosis of acute myelogenous leukemia (AML) being treated with chemotherapy presented with a lesion on her lower back within the confines of a newly inked tattoo.
  • Five days after tattoo placement, she developed an oozing, indurated, necrotic plaque at the site.
  • Four days later, she developed chills, fever, and neutropenia.
  • A skin biopsy was performed and was consistent with pyoderma gangrenosum (PG) or neutrophilic dermatoses.
  • PG is an inflammatory skin disease associated with both cutaneous trauma and systemic disease, including hematologic malignancy.
  • PG after tattoo placement, in both healthy patients and those with hematologic malignancies, has, to our knowledge, not yet been described in the literature.
  • While further studies are necessary to investigate the link between PG and tattooing, oncologists may wish to counsel patients with leukemia to refrain from obtaining new tattoos.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Pyoderma Gangrenosum / etiology. Tattooing / adverse effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Pyoderma gangrenosum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273727.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Rodríguez Bujaldon A, Vázquez C, Jiménez-Puya R, Galán M, Vélez A, Moreno JC, Rojas R, Arqueros V: [Neutrophilic eccrine hidradenitis secondary to thioguanine in a neutropenic patient]. Actas Dermosifiliogr; 2005 Nov;96(9):583-5
Hazardous Substances Data Bank. THIOGUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neutrophilic eccrine hidradenitis secondary to thioguanine in a neutropenic patient].
  • [Transliterated title] Hidradenitis ecrina neutrofílica secundaria a tioguanina en paciente neutropénico.
  • Neutrophilic eccrine hidradenitis (NEH) is an infrequent, self-limited inflammatory dermatosis characterized by a neutrophilic infiltrate around the eccrine glands.
  • Clinically, it presents with different types of lesions.
  • NEH occurs most frequently in patients who have undergone chemotherapy for hematologic neoplasms.
  • We present a case of NEH in a 70-year-old neutropenic male who received thioguanine for acute myeloid leukemia.
  • [MeSH-minor] Aged. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476301.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


19. Requena L, Kutzner H, Palmedo G, Pascual M, Fernández-Herrera J, Fraga J, García-Díez A, Yus ES: Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol; 2005 Jul;141(7):834-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes.
  • OBJECTIVE: To describe a series of 41 patients with fresh lesions of Sweet syndrome in which the histopathologic study demonstrated an inflammatory infiltrate mostly composed of histiocytoid mononuclear cells.
  • DESIGN: Histopathologic, immunohistochemical, and cytogenetic studies of the inflammatory infiltrate in a case series of histiocytoid Sweet syndrome.
  • METHODS: Conventional histopathologic study as well as immunohistochemical investigations were performed using the alkaline phosphatase antialkaline phosphatase technique with a large panel of antibodies.
  • RESULTS: Immunohistochemical studies demonstrated that most cells of the infiltrate showed immunoreactivity for CD15, CD43, CD45, CD68, MAC-386, HAM56, and lysozyme, which is consistent with a monocytic-histiocytic immunoprofile.
  • However, intense myeloperoxidase reactivity was detected in most of the cells with histiocytic appearance, which raised the possibility of specific cutaneous involvement by myelogenous leukemia.
  • Nevertheless, cytologic peripheral blood examinations, fluorescent in situ hybridization studies to investigate the bcr/abl gene fusion, and follow-up of the patients, taken all together, ruled out this possibility.
  • CONCLUSIONS: This case series demonstrates that some fresh cutaneous lesions of Sweet syndrome are histopathologically characterized by an infiltrate mostly composed of cells that may be misinterpreted as histiocytes, when in fact they are immature myeloid cells.
  • We named this histopathologic variant histiocytoid Sweet syndrome, which should not be mistaken with leukemia cutis or other inflammatory dermatoses that are histopathologically characterized by histiocytes interstitially arranged between collagen bundles of the dermis.
  • [MeSH-major] Diclofenac / analogs & derivatives. Histiocytes / pathology. Sweet Syndrome / drug therapy. Sweet Syndrome / pathology
  • [MeSH-minor] Acetaminophen / administration & dosage. Administration, Oral. Adult. Aged. Biopsy, Needle. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prednisone / administration & dosage. Severity of Illness Index. Treatment Outcome

  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Dermatol. 2014 Feb;53(2):e80-2 [23330976.001]
  • [CommentIn] Arch Dermatol. 2005 Jul;141(7):893-5 [16027307.001]
  • (PMID = 16027297.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 144O8QL0L1 / Diclofenac; 362O9ITL9D / Acetaminophen; RPK779R03H / aceclofenac; VB0R961HZT / Prednisone
  •  go-up   go-down


20. Tojo M, Iwatsuki K, Furukawa H, Takahashi M, Kaneko F: Neutrophilic eccrine hidradenitis in actinic reticuloid syndrome. Eur J Dermatol; 2002 Mar-Apr;12(2):198-200
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis in actinic reticuloid syndrome.
  • Neutrophilic eccrine hidradenitis (NEH) is a rare, transient complication, which usually occurs in patients with leukemia receiving various chemotherapeutic regimens.
  • We report the first case of NEH arising in a patient with actinic reticuloid syndrome who had been treated with methotrexate.
  • [MeSH-major] Hidradenitis / pathology. Methotrexate / adverse effects. Photosensitivity Disorders / drug therapy
  • [MeSH-minor] Diagnosis, Differential. Exanthema / etiology. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11872424.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


21. Bhave AA, Rao RG, Patil GT: Rare presentation of leucocytosis. J Assoc Physicians India; 2006 Nov;54:881-2
Hazardous Substances Data Bank. Allopurinol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 44 years man who presented to us with persistent leucocytosis.
  • Following relevant investigations, we diagnosed him to have Chronic Neutrophilic Leukaemia (CNL); a rare haematological disorder.
  • Ten months later, he remains non-responsive to standard line of treatment.
  • [MeSH-major] Leukemia, Neutrophilic, Chronic / diagnosis. Leukemia, Neutrophilic, Chronic / drug therapy
  • [MeSH-minor] Adult. Allopurinol / therapeutic use. Humans. Hydroxyurea / therapeutic use. Leukocytosis / diagnosis. Male. Prognosis. Vitamins / therapeutic use

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249258.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Vitamins; 63CZ7GJN5I / Allopurinol; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


22. Chiang M, Fleming M: The pseudo-Pelger-Huët anomaly in pyoderma gangrenosum associated with myelodysplastic syndrome. Am J Dermatopathol; 2007 Jun;29(3):293-5
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pseudo-Pelger-Huët anomaly in pyoderma gangrenosum associated with myelodysplastic syndrome.
  • We report a case of pyoderma gangrenosum in which most of the neutrophils exhibited the pseudo-Pelger-Huët (pPH) anomaly, a cytologic abnormality affecting the neutrophil nucleus.
  • The pPH anomaly is important because it is found mostly in patients with myelodysplastic syndromes or myeloid leukemias.
  • These patients are also at risk for developing neutrophilic dermatosis as well as leukemia cutis, the main differential diagnosis.
  • In our case, the proper diagnosis was made with the help of immunohistochemistry.
  • [MeSH-minor] Administration, Oral. Administration, Topical. Aged, 80 and over. Fatal Outcome. Glucocorticoids / therapeutic use. Humans. Leg Ulcer / drug therapy. Leg Ulcer / etiology. Leg Ulcer / pathology. Male. Prednisone / therapeutic use


23. Ng ES, Aw DC, Tan KB, Poon ML, Yap ES, Liu TC, Tan LK, Chng WJ, Koh LP: Neutrophilic eccrine hidradenitis associated with decitabine. Leuk Res; 2010 May;34(5):e130-2
Hazardous Substances Data Bank. DAPSONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis associated with decitabine.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Azacitidine / analogs & derivatives. Hidradenitis / chemically induced. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adult. Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dapsone / therapeutic use. Female. Humans. Prednisolone / therapeutic use

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20022375.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; 776B62CQ27 / decitabine; 8W5C518302 / Dapsone; 9PHQ9Y1OLM / Prednisolone; M801H13NRU / Azacitidine
  •  go-up   go-down


24. Chevalier N, Solari ML, Becker H, Pantic M, Gärtner F, Maul-Pavicic A, Hübner J, Wäsch R, Schmitt-Gräff A, Lübbert M: Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib. Leukemia; 2010 Oct;24(10):1779-81
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.
  • [MeSH-major] Cell Differentiation / drug effects. Granulocytes / cytology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / pathology. Neutrophils / cytology. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. Translocation, Genetic
  • [MeSH-minor] Blast Crisis / drug therapy. Blast Crisis / genetics. Blast Crisis / pathology. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Dasatinib. Flow Cytometry. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811401.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.1 / Protein-Tyrosine Kinases; RBZ1571X5H / Dasatinib
  •  go-up   go-down






Advertisement